Revenue
No reported data
Cadrenal Therapeutics, Inc. (CVKD)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2008 | |
|---|---|---|---|---|---|
| Research & development | $4.1M | $4.2M | $200,000 | $392,859 | $200,000 |
| Operating expenses | $13.5M | $11.0M | $7.6M | $2.7M | — |
| Operating income | −$13.5M | −$11.0M | −$7.6M | −$2.7M | — |
| Net income | −$13.2M | −$10.7M | −$8.4M | −$6.7M | — |
| Basic EPSper diluted share | -$6.64 | -$8.73 | -$9.29 | -$0.85 | — |
| Diluted EPSper diluted share | -$6.64 | -$8.73 | -$9.29 | -$0.85 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Pham Quang XChairman, CEO and Interim CFO | SellCommon Stock | 9.0K | $3.05 | $27.5K | 106.0K |
| Jun 25, 2026Form 4 · 10b5-1 | Pham Quang XChairman, CEO and Interim CFO | SellCommon Stock | 2.1K | $3.00 | $6.4K | 115.0K |
| Jun 23, 2026Form 4 · 10b5-1 | Pham Quang XChairman, CEO and Interim CFO | SellCommon Stock | 2.3K | $3.20 | $7.3K | 117.1K |
| Jun 22, 2026Form 4 · 10b5-1 | Pham Quang XChairman, CEO and Interim CFO | SellCommon Stock | 9.2K | $3.55 | $32.5K | 119.4K |
| Jun 17, 2026Form 4 · 10b5-1 | Pham Quang XChairman, CEO and Interim CFO | SellCommon Stock | 513 | $3.16 | $1.6K | 128.6K |